Agilent Technologies (A)
Health Care · $46.9B market cap · SEC CIK 0001090872
fundamentals score out of 100
Next reports on Nov 23, 2026, after the close, with analysts expecting $1.76 in earnings per share.
The case for A
- Generated $1.2B of free cash flow in FY2025, 17% of revenue.
- Revenue growing 8.6% year over year.
- Return on equity of 20%.
- Current assets cover the near-term bills 2.1 times over.
- Within 1% of its 52-week high: the trend is up.
The case against
- Pricey at 32.6× earnings, against a long-run market average nearer 20×.
- Priced at 6.4× sales with revenue growing only 8.6%.
- Free-cash-flow yield of 2.5% is lower than 85% of Health Care companies.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 37 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 52 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 73 |
| Momentumhow the price has behaved lately | 89 |
| Stabilityhow violently it moves, what it owes and what it pays you | 47 |
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
Key numbers
| Price / earnings | 32.6× |
|---|---|
| Price / book | 5.31× |
| Price / sales | 6.4× |
| Revenue growth (YoY) | +8.6% |
| EPS growth (YoY) | +18.7% |
| Gross margin | 54% |
| Operating margin | 22% |
| Net margin | 20% |
| Return on equity | 20% |
| Debt / equity | 0.54× |
| Current ratio | 2.05 |
| Dividend yield | 0.75% |
| Beta | 1.27 |
| 52-week range | $108.35 – $163.75 |
| Position in that range | 100% of the way up |
| 3-month return | +27.5% |
| 1-year return | +28.2% |
Five years of financials, as filed
Pulled from Agilent Technologies's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $6.9B | $6.5B | $6.8B | $6.8B | $6.3B |
| Operating income | $1.5B | $1.5B | $1.4B | $1.6B | $1.3B |
| Net income | $1.3B | $1.3B | $1.2B | $1.3B | $1.2B |
| Operating cash flow | $1.6B | $1.8B | $1.8B | $1.3B | $1.5B |
| Capital expenditure | $407M | $378M | $298M | $291M | $188M |
| Total assets | $12.8B | $11.9B | $10.9B | $10.9B | $10.3B |
| Total liabilities | $5.9B | $5.9B | $4.8B | $5.3B | $5.2B |
| Shareholder equity | $6.9B | $6.0B | $6.2B | $5.6B | $5.2B |
| Cash | $1.8B | $1.5B | $1.7B | $1.3B | $1.1B |
| Long-term debt | $3.0B | $3.3B | $2.6B | $2.7B | $2.7B |
| Free cash flow | $1.2B | $1.4B | $1.5B | $1.0B | $1.3B |
| Operating margin | 21.3% | 22.9% | 19.8% | 23.6% | 21.3% |
| Net margin | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% |
| Diluted shares | 285M | 291M | 296M | 300M | 307M |
Share count is down 7.2% over 4 years. Buybacks have been shrinking the pie.
What Agilent Technologies says it does
Overview Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy. Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment. Our chemistries and supplies, laboratory automation, and software and informatics divisions moved from our former Life Sciences and Applied Markets segment to our Agilent CrossLab segment. The remaining divisions in our former Life Sciences and Applied Markets segment which includes our…
Risk factors A lists in its 10-K
- General economic conditions may adversely affect our operating results and financial condition
- Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated
- Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of operations
- Demand for some of our products and services depends on the capital spending policies of our customers, research and development budgets and on government funding policies
- Recent and dynamic government rule making and policy changes could increase our costs, affect our markets and customers and impact our results of operations
- Failure to adjust our purchases due to changing market conditions or failure to accurately estimate our customers' demand could adversely affect our income
- Our business will suffer if we are not able to retain and hire key personnel
- Our strategic initiatives to adjust our cost structure could have long-term adverse effects on our business, and we may not realize the operational or financial benefits from such actions
- Our acquisitions, strategic investments and alliances, joint ventures, exiting of businesses and divestitures may result in financial results that are different than expected
- The impact of consolidation and acquisitions of competitors is difficult to predict and may harm our business
- Public health crises may adversely impact, and pose risks to, certain elements of our business, results of operations and financial condition, the nature and extent of which are highly uncertain and unpredictable
- Regulatory, Legal and Compliance Risks
- Some of our products are subject to particularly complex regulations such as regulations of toxic substances, and failure to comply with such regulations could harm our business
- Our business may suffer if we fail to comply with government contracting laws and regulations